高 荣,程芹芹,白 玲,祖丽皮亚·达木拉,帕尔哈提·阿布力米提.耐药大环内酯类肺炎支原体肺炎患儿外周血HMGB1表达与预后转归的关系[J].现代生物医学进展英文版,2021,(19):3690-3693. |
耐药大环内酯类肺炎支原体肺炎患儿外周血HMGB1表达与预后转归的关系 |
The Relationship between the Expression of HMGB1 in Peripheral Blood and Prognosis of Children with Drug-resistant Macrolide-type Mycoplasma Pneumoniae |
Received:March 05, 2021 Revised:March 28, 2021 |
DOI:10.13241/j.cnki.pmb.2021.19.018 |
中文关键词: 耐药大环内酯类 肺炎支原体肺炎 小儿 高迁移率族蛋白B1 急性生理与慢性健康评分 相关性 |
英文关键词: Drug-resistant macrolides Mycoplasma pneumoniae pneumonia children High mobility group protein B1 Acute physiology and chronic health scores Correlation |
基金项目:新疆维吾尔自治区自然科学基金项目(2018D01C123) |
|
Hits: 741 |
Download times: 369 |
中文摘要: |
摘要 目的:探讨耐药大环内酯类肺炎支原体(Mycoplasma pneumoniae,MP)肺炎患儿外周血高迁移率族蛋白 B1(high mobility group protein B1,HMGB1)表达与预后转归的关系。方法:2017年1月-2019年12月选择在新疆维吾尔自治区人民医院诊治的耐药大环内酯类肺炎支原体肺炎患儿78例、非耐药大环内酯类肺炎支原体肺炎患儿78例与健康儿童78例分别作为耐药组、非耐药组与对照组,检测三组外周血HMGB1表达水平,调查耐药组患儿的急性生理与慢性健康(Acute Physiology and Chronic Health Evaluation,APACHEⅡ)评分与随访预后并进行相关性分析。结果:耐药组、非耐药组的血清HMGB1水平高于对照组(P<0.05),耐药组高于非耐药组(P<0.05)。随着入院时间的增加,耐药组患儿的APACHEⅡ评分逐渐降低,对比差异有统计学意义(P<0.05)。随访到2020年5月1日,耐药组患儿死亡2例,死亡率为2.6 %。在耐药组中,Pearson相关分析显示外周血HMGB1与APACHEⅡ评分、发热持续时间、住院时间、肺部病变个数存在相关性(P<0.05)。受试者工作特征(receiver operating characteristic,ROC)曲线分析显示外周血HMGB1、APACHEⅡ评分预测患儿死亡的最大截面积为0.872(95 %CI:0.729-0.878)和0.889(95 %CI:0.813-0.941)。结论:耐药大环内酯类肺炎支原体肺炎患儿外周血HMGB1呈现高表达状况,与患儿的APACHEⅡ评分呈现正相关性,以上结果有助于预测患儿的随访预后,并为进一步明确该病的发生机制提供一定的借鉴。 |
英文摘要: |
ABSTRACT Objective: To investigate the relationship between the expression of high mobility group protein B1 (HMGB1) and the prognosis of children with drug-resistant Mycoplasma pneumoniae (MP) pneumonia. Methods: From January 2017 to December 2019, 78 cases of children with drug-resistant macrolide Mycoplasma pneumoniae pneumonia, 78 cases of children with non-drug-resistant macrolide mycoplasma pneumoniae pneumonia and 78 cases of healthy children were selected for diagnosis and treatment in People's Hospital of Xinjiang Uygur Autonomous Region were selected as drug-resistant group, non-drug-resistant group and control group. The expression levels of HMGB1 in the peripheral blood of the three groups were detected, and were to investigate the Acute Physiology and Chronic Health Evaluation (APACHEⅡ) score and followed-up prognosis of children in the drug-resistant group and given correlation analysis. Results: The serum HMGB1 levels in the drug-resistant group and non-resistant group were higher than those in the control group (P<0.05), and the drug-resistant group were higher than the non-resistant group (P<0.05). With the increased of admission time, the APACHEⅡ scores of children in the drug-resistant group were gradually decreased, and the difference were statistically significant (P<0.05). Followed-up until May 1, 2020, there were 2 children in the drug-resistant group died, with the mortality rate of 2.6 %. In the drug resistance group, Pearson correlation analysis showed that peripheral blood HMGB1 were correlated with APACHEⅡ score, duration of fever, length of hospitalization, and number of lung lesions (P<0.05). Receiver operating characteristic(ROC) curve analysis showed that the maximum cross-sectional area predicted by the peripheral blood HMGB1 and APACHEⅡ scores were 0.872 (95 %CI: 0.729-0.878) and 0.889 (95 %CI: 0.813-0.941). Conclusion: Peripheral blood HMGB1 are highly expressed in children with drug-resistant macrolide Mycoplasma pneumoniae pneumonia, which are positively correlated with the children's APACHE Ⅱ score, and can also predict the follow-up prognosis of the children. The above results are helpful to predict the follow-up prognosis of children, and provide a certain reference for further clarifying the occurrence mechanism of the disease. |
View Full Text
View/Add Comment Download reader |
Close |